CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

UK’s Quell Therapeutics raises £156m Series B

By Jenni Reid

07:40, 29 November 2021

Quell Therapeutics logo on a presentation screengrab
London-based Quell Therapeutics has completed a Series B funding round led by Jeito Capital and others – Photo: Quell Therapeutics

British biotech company Quell Therapeutics has raised £156m ($117m) in oversubscribed Series B funding.

Quell said it would use the financing to fund further clinical trials of a cell therapy that would prevent organ rejection in liver transplant patients, preventing the need for lifelong immunosuppression.

The round was led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors, Fidelity Management & Research Company. 

The company will also advance its pipeline in transplantation, neuroinflammatory diseases and autoimmune diseases. 

Treg cell

London-based Quell launched in March 2019 with £34m in Series A funding from FTSE 250 investor Syncona, which also participated in the Series B. 

Quell specialises in regulatory T (Treg) cell therapies which are used to suppress overactive immune responses and promote tissue repair. 


0.63 Price
+0.780% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040


39,676.60 Price
+0.070% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Its total £60.4m Series A funding was the largest ever within the Treg field. 

Paris-based private equity firm Jeito today said its technology allowed it to design, engineer, and manufacture Treg products with greater stability, persistence and potency. 

Growth ambitions

Jeito CEO Rafaèle Tordjman commented: “Our investment in Quell is testament of our ambition to continue building a strong portfolio of companies with the potential of becoming market leaders.”

Iain McGill, Quell Therapeutics CEO, said: “We are proud to have the support of this premiere syndicate of investors as we drive forward to our next stage of growth. 

“With this financing, we have the full suite of capabilities – capital, cutting-edge science, and a world-class team – to advance our pipeline and platform to key milestones on our path ultimately to deliver potentially transformative therapies to patients suffering from diseases caused by immune dysregulation.”

Read more: Texas biotech company Vaxxinity announces IPO terms

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading